文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症COVID-19相关念珠菌血症的危险因素与临床结局

Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19.
PubMed 文献 · Crit Care Explor · 2022-09-13
一句话结论重症COVID-19合并念珠菌血症患者院内死亡率显著高于无念珠菌血症者(68% vs 40%),中心静脉导管、生物制剂和肌松药为独立危险因素。

该多中心病例对照研究纳入275例重症COVID-19患者,其中91例发生念珠菌血症、184例未发生,评估危险因素与临床结局。念珠菌血症组院内死亡率显著高于对照组(68% vs 40%,p<0.01)。白色念珠菌最常见(53%),其次为光滑念珠菌(19%)。中心静脉导管、生物制剂和肌松药使用是念珠菌血症的独立危险因素。作者认为COVID-19后念珠菌血症需临床关注和患者监测,其危险因素与传统住院患者念珠菌血症危险因素基本一致。

要点

  • 重症COVID-19合并念珠菌血症患者院内死亡率为68%,显著高于无念珠菌血症者的40%(p<0.01)。
  • 念珠菌血症组中白色念珠菌最常见(53%),其次为光滑念珠菌(19%)。
  • 中心静脉导管、生物制剂和肌松药使用是重症COVID-19患者发生念珠菌血症的独立危险因素。
  • 93%的患者在念珠菌血症发生前接受过抗生素治疗,约四分之一患者接受过COVID-19生物制剂治疗。
  • 作者认为COVID-19后念珠菌血症需临床考虑和患者监测,其危险因素与传统住院患者念珠菌血症危险因素基本一致。

适用人群与场景

  • 2020年8月至2021年8月期间住院的重症COVID-19患者,多中心病例对照研究纳入275例,其中91例发生念珠菌血症、184例未发生。

研究设计与关键结果

  • 多中心病例对照研究纳入275例重症COVID-19患者,比较91例后续发生念珠菌血症者与184例未发生者的危险因素和临床结局。
  • 念珠菌血症组院内死亡率为68%,对照组为40%,两组差异显著(p<0.01)。
  • 病原学方面白色念珠菌最常见(53%),其次为光滑念珠菌(19%)。
  • 93%的患者在念珠菌血症发生前接受过抗生素治疗,约四分之一患者接受过COVID-19生物制剂治疗。
  • 中心静脉导管、生物制剂和肌松药使用是念珠菌血症的独立危险因素。

证据类型、等级与局限

  • 证据类型:多中心病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为COVID-19感染后念珠菌血症是需要临床考虑和患者监测的问题。
  • 作者指出COVID-19感染背景下发生念珠菌血症的危险因素与传统住院患者念珠菌血症的危险因素基本一致。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains unclear.

OBJECTIVES: To describe clinical characteristics, outcomes and risk factors of candidemia among patients hospitalized with severe COVID-19.

DESIGN SETTING AND PARTICIPANTS: A multicenter, case-control study of patients with severe COVID-19 was conducted to evaluate risk factors and clinical outcomes in patients who developed candidemia between August 2020 and August 2021.

MAIN OUTCOMES AND MEASURES: Chart review evaluating institutional and patient demographics, clinical and mycological characteristics, concomitant interventions (antibiotics, immunosuppressive agents, parenteral nutrition, degree of oxygen support, mechanical ventilation, surgery), treatment regimens, and outcomes (length of stay and discharge disposition).

RESULTS: A total of 275 patients were enrolled in the study, including 91 patients with severe COVID-19 and subsequent candidemia and 184 with severe COVID-19 without candidemia. Most patients received antibiotics prior to candidemia episode (93%), while approximately one-quarter of patients received biologic for COVID-19. In-hospital mortality was significantly higher in the cases compared with the controls (68% vs 40%; p < 0.01). Candida albicans was the most common (53%), followed by C. glabrata (19%). Use of central lines, biologic, and paralytics were independent risk factors for candidemia.

CONCLUSIONS AND RELEVANCE: Candidemia following COVID-19 infection is a concern that requires clinical consideration and patient monitoring. Risk factors for the development of candidemia in the setting of COVID-19 infection are largely consistent with traditional risk factors for candidemia in hospitalized patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Dixit D, Jen P, Maxwell TD, et al. Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19. Crit Care Explor. 2022. PMID: 36119397. doi:10.1097/CCE.0000000000000762

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。